231 related articles for article (PubMed ID: 22554312)
1. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy.
Amthor H; Hoogaars WM
Curr Gene Ther; 2012 Jun; 12(3):245-59. PubMed ID: 22554312
[TBL] [Abstract][Full Text] [Related]
2. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
3. Effects of muscular dystrophy, exercise and blocking activin receptor IIB ligands on the unfolded protein response and oxidative stress.
Hulmi JJ; Hentilä J; DeRuisseau KC; Oliveira BM; Papaioannou KG; Autio R; Kujala UM; Ritvos O; Kainulainen H; Korkmaz A; Atalay M
Free Radic Biol Med; 2016 Oct; 99():308-322. PubMed ID: 27554968
[TBL] [Abstract][Full Text] [Related]
4. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
5. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy.
Relizani K; Mouisel E; Giannesini B; Hourdé C; Patel K; Morales Gonzalez S; Jülich K; Vignaud A; Piétri-Rouxel F; Fortin D; Garcia L; Blot S; Ritvos O; Bendahan D; Ferry A; Ventura-Clapier R; Schuelke M; Amthor H
Mol Ther; 2014 Aug; 22(8):1423-1433. PubMed ID: 24861054
[TBL] [Abstract][Full Text] [Related]
6. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo.
Béchir N; Pecchi E; Vilmen C; Le Fur Y; Amthor H; Bernard M; Bendahan D; Giannesini B
FASEB J; 2016 Oct; 30(10):3551-3562. PubMed ID: 27416839
[TBL] [Abstract][Full Text] [Related]
7. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
8. Postnatal Hyperplasic Effects of ActRIIB Blockade in a Severely Dystrophic Muscle.
Nielsen C; Potter RM; Borowy C; Jacinto K; Kumar R; Carlson CG
J Cell Physiol; 2017 Jul; 232(7):1774-1793. PubMed ID: 27859236
[TBL] [Abstract][Full Text] [Related]
9. Blocking the myostatin signal with a dominant negative receptor improves the success of human myoblast transplantation in dystrophic mice.
Fakhfakh R; Michaud A; Tremblay JP
Mol Ther; 2011 Jan; 19(1):204-10. PubMed ID: 20700111
[TBL] [Abstract][Full Text] [Related]
10. A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation.
Sun Z; Xu D; Zhao L; Li X; Li S; Huang X; Li C; Sun L; Liu B; Jiang Z; Zhang L
Br J Pharmacol; 2022 Mar; 179(6):1237-1250. PubMed ID: 34553378
[TBL] [Abstract][Full Text] [Related]
11. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy.
Pistilli EE; Bogdanovich S; Goncalves MD; Ahima RS; Lachey J; Seehra J; Khurana T
Am J Pathol; 2011 Mar; 178(3):1287-97. PubMed ID: 21356379
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ.
Lamar KM; Bogdanovich S; Gardner BB; Gao QQ; Miller T; Earley JU; Hadhazy M; Vo AH; Wren L; Molkentin JD; McNally EM
PLoS Genet; 2016 May; 12(5):e1006019. PubMed ID: 27148972
[TBL] [Abstract][Full Text] [Related]
13. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
14. Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice.
Fakhfakh R; Lee SJ; Tremblay JP
Cell Transplant; 2012; 21(7):1419-30. PubMed ID: 22449443
[TBL] [Abstract][Full Text] [Related]
15. Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.
Liu M; Hammers DW; Barton ER; Sweeney HL
PLoS One; 2016; 11(11):e0166803. PubMed ID: 27870893
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of myostatin reverses muscle fibrosis through apoptosis.
Bo Li Z; Zhang J; Wagner KR
J Cell Sci; 2012 Sep; 125(Pt 17):3957-65. PubMed ID: 22685331
[TBL] [Abstract][Full Text] [Related]
17. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
[TBL] [Abstract][Full Text] [Related]
18. Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.
Morine KJ; Bish LT; Pendrak K; Sleeper MM; Barton ER; Sweeney HL
PLoS One; 2010 Feb; 5(2):e9176. PubMed ID: 20161803
[TBL] [Abstract][Full Text] [Related]
19. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.
Morine KJ; Bish LT; Selsby JT; Gazzara JA; Pendrak K; Sleeper MM; Barton ER; Lee SJ; Sweeney HL
Muscle Nerve; 2010 Nov; 42(5):722-30. PubMed ID: 20730876
[TBL] [Abstract][Full Text] [Related]
20. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice.
Dumonceaux J; Marie S; Beley C; Trollet C; Vignaud A; Ferry A; Butler-Browne G; Garcia L
Mol Ther; 2010 May; 18(5):881-7. PubMed ID: 20104211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
